4.42 USD
+0.26 (+6.25%)
At close: Jan 30, 2026
4.21 USD
-0.21 (-4.75%)
After Hours: 1/30/2026, 8:22:40 PM
Overall UPC gets a fundamental rating of 3 out of 10. We evaluated UPC against 190 industry peers in the Pharmaceuticals industry. The financial health of UPC is average, but there are quite some concerns on its profitability. UPC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- UPC had positive earnings in the past year.
- In the past year UPC has reported a negative cash flow from operations.
- In multiple years UPC reported negative net income over the last 5 years.
- In multiple years UPC reported negative operating cash flow during the last 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 1.35%, UPC belongs to the top of the industry, outperforming 80.53% of the companies in the same industry.
- With an excellent Return On Equity value of 1.97%, UPC belongs to the best of the industry, outperforming 81.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | 1.97% | ||
| ROIC | N/A |
ROA(3y)-14.43%
ROA(5y)-0.18%
ROE(3y)-20.51%
ROE(5y)-1.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- UPC has a better Profit Margin (5.65%) than 82.11% of its industry peers.
- UPC has a Gross Margin of 30.41%. This is comparable to the rest of the industry: UPC outperforms 57.37% of its industry peers.
- In the last couple of years the Gross Margin of UPC has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 5.65% | ||
| GM | 30.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.65%
GM growth 5Y-8.51%
2. Health
2.1 Basic Checks
- UPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, UPC has more shares outstanding
- The number of shares outstanding for UPC has been increased compared to 5 years ago.
- Compared to 1 year ago, UPC has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.37, we must say that UPC is in the distress zone and has some risk of bankruptcy.
- UPC has a Altman-Z score (0.37) which is comparable to the rest of the industry.
- UPC has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.04, UPC is in line with its industry, outperforming 53.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.37 |
ROIC/WACCN/A
WACC6.51%
2.3 Liquidity
- A Current Ratio of 2.78 indicates that UPC has no problem at all paying its short term obligations.
- UPC's Current ratio of 2.78 is in line compared to the rest of the industry. UPC outperforms 49.47% of its industry peers.
- UPC has a Quick Ratio of 2.62. This indicates that UPC is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of UPC (2.62) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 106.13% over the past year.
- The Revenue for UPC has decreased by -27.81% in the past year. This is quite bad
- UPC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.08% yearly.
EPS 1Y (TTM)106.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.56%
Revenue 1Y (TTM)-27.81%
Revenue growth 3Y-21.71%
Revenue growth 5Y-7.08%
Sales Q2Q%-28.96%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 0.02, the valuation of UPC can be described as very cheap.
- Based on the Price/Earnings ratio, UPC is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
- UPC's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.30.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.02 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for UPC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UNIVERSE PHARMACEUTICALS INC / UPC FAQ
What is the ChartMill fundamental rating of UNIVERSE PHARMACEUTICALS INC (UPC) stock?
ChartMill assigns a fundamental rating of 3 / 10 to UPC.
Can you provide the valuation status for UNIVERSE PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSE PHARMACEUTICALS INC (UPC). This can be considered as Overvalued.
How profitable is UNIVERSE PHARMACEUTICALS INC (UPC) stock?
UNIVERSE PHARMACEUTICALS INC (UPC) has a profitability rating of 3 / 10.
What is the valuation of UNIVERSE PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UNIVERSE PHARMACEUTICALS INC (UPC) is 0.02 and the Price/Book (PB) ratio is 0.04.